Newsroom

For media inquiries, please contact 340B Health Senior Director of Communications David Glendinning at david.glendinning@340bhealth.org or 202-536-2289.

• STATEMENT ON UCB RESTRICTING 340B DISCOUNTS THROUGH COMMUNITY-BASED PHARMACIES

  November 23, 2021 in 340B Health News Releases

• As Big Pharma and Hospitals Battle Over Drug Discounts, Patients Miss Out on Millions in Benefits

  November 16, 2021 in 340B in the News

• STATEMENT ON FEDERAL COURT OPINION IN NOVARTIS AND UNITED THERAPEUTICS 340B COMMUNITY PHARMACY LAWSUITS

  November 06, 2021 in 340B Health News Releases

• STATEMENT ON FEDERAL COURT OPINION IN SANOFI AND NOVO NORDISK 340B COMMUNITY PHARMACY LAWSUITS

  November 05, 2021 in 340B Health News Releases

• REPORT: 340B HOSPITALS ARE DIRECTING SAVINGS TOWARD THEIR COMMUNITIES’ UNIQUE NEEDS

  November 03, 2021 in 340B Health News Releases

• STATEMENT ON MEDICARE PAYMENT CUTS TO 340B HOSPITALS IN 2022

  November 02, 2021 in 340B Health News Releases

• STATEMENT ON FEDERAL COURT OPINION IN 340B COMMUNITY PHARMACY LAWSUIT

  October 30, 2021 in 340B Health News Releases

• 340B HEALTH BOARD ELECTS TWO NEW MEMBERS

  October 15, 2021 in 340B Health News Releases

• How drugmaker restrictions on 340B discounts affect hospital pharmacies: 5 systems weigh in

  October 04, 2021 in 340B in the News

• STATEMENT ON FEDERAL 340B ENFORCEMENT ACTIONS AGAINST BOEHRINGER INGELHEIM

  October 04, 2021 in 340B Health News Releases

• SIX DRUG COMPANIES REFERRED FOR PENALTIES FOR CONTINUED VIOLATIONS OF FEDERAL LAW ON 340B PRICING

  September 22, 2021 in 340B Health News Releases

• DIABETES DRUGS HEAVILY IMPACTED BY DRUGMAKERS’ 340B POLICIES

  September 15, 2021 in 340B Health News Releases